Delayed hospital project to cost three times more than expected

Aberdeen's Baird Family Hospital and Anchor Cancer Centre, originally budgeted at up to £134m and due to open in 2020, now have an updated project investment of approximately £423.6m after delays and construction problems (water, ventilation and design issues); work only began in 2021 and openings are now staggered (Anchor later this year, maternity hospital next year). The more-than-threefold cost increase and prolonged timetable raise fiscal pressure on the Scottish government and NHS Grampian, invite political scrutiny from opposition parties and highlight contractor/management risk on large public-health infrastructure projects.

Analysis

Market structure: Direct losers are Scottish public finances and regional NHS contractors — the £424m vs £134m blowout forces either budget reallocations or additional funding, pressuring local suppliers and smaller contractors with fixed-price exposure. Winners are diversified materials and equipment suppliers (pricing power) and large-tier contractors able to renegotiate change orders; expect procurement to favor larger, balance-sheet-strong firms over niche players within 3–12 months.

Risk assessment: Tail risks include a national procurement inquiry that freezes new projects (low probability, high impact) and a fiscal re-prioritisation that cuts other Scottish capex by >10% in a single budget cycle (6–12 months). Immediate effects (days) are political headline risk and tender delays; short-term (weeks–months) are margin squeezes for mid-cap contractors and 10–30bp widening in Scottish/UK regional credit spreads; long-term (quarters–years) are higher contract pricing and stricter procurement terms.

Trade implications: Tactical trade is to underweight/hedge small-to-mid UK contractors (KIE, GFRD) and rotate into materials/aggregates (CRH) and large diversified contractors (BBY) with >50% public-sector exposure only after price dislocation. Use 3-month put spreads to hedge downside in KIE/GFRD and 6–12 month call spreads on CRH to play sustained materials pricing; size positions to 1–3% of portfolio and target 8–15% asymmetric returns.

Contrarian angles: Consensus will over-penalise all contractors; the miss is that large contractors with diversified UK/intl backlog (BBY, CRH) will see contract renegotiation upside and quicker recovery — a 20–30% share-price gap would be a buy signal. Historical parallels: Crossrail/large public projects recovered equity value post-settlement; if procurement reforms favor clearer change-order mechanisms, premium accrual to big-cap contractors and materials suppliers can materialise within 6–12 months.

Key Decisions for Investors

• Establish a 2% short exposure to Kier Group (KIE:LSE) and Galliford Try (GFRD:LSE) combined (1% each) via 3-month put spreads (buy 10% OTM, sell 20% OTM) to limit cost, targeting a 10–20% downside if delays propagate over 3 months.
• Open a 2–3% long position in CRH (NYSE:CRH) via a 6–12 month 50/60 call spread (buy $50 call, sell $60 call or nearest strikes) to capture an anticipated 8–15% upside from sustained materials pricing and reallocated regional projects.
• Buy a 1.5% long in Balfour Beatty (BBY:LSE) on weakness only: accumulate if price drops 20–30% from current levels, with a 6–12 month horizon — large-cap diversification and renegotiation leverage likely to outperform small specialists.
• Avoid new >1% direct exposure to small, Scotland-focused subcontractors until 30–60 days after publication of any procurement/audit report; if audit allocates client-side fault, pivot to selective long positions in rehabilitated names on 30–50% retracement.